EKEiji Kojima

Eiji Kojima

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eiji Kojima has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Validation of the Japanese Severe Respiratory Insufficiency Questionnaire in hypercapnic patients with noninvasive ventilation

    by Toru Oga, Hiroyuki Taniguchi, Hideo Kita, Tomomasa Tsuboi, Keisuke Tomii, Morihide Ando, Eiji Kojima, Hiromi Tomioka, Yoshio Taguchi, Yusuke Kaji, et al.


  • A propensity score-matched comparison of the efficacies of OK-432 and talc slurry for pleurodesis for malignant pleural effusion induced by lung adenocarcinoma

    by Kango Nohara, Kazuto Takada, Eiji Kojima, Kiyoko Ninomiya, Shoko Miyamatsu, Takahiro Shimizu, Tsutomu Sakurai, Takaaki Mizuno, Yuuki Yamashita


    • 1 May 2016
      • Vol. 43  (5) , 613-5

    [A Case of Acute Arterial Occlusion of the Lower Limb during Chemotherapy for Lung Cancer].

    by Kentaro Tanaka, Kazuto Takada, Eiji Kojima, Takahiro Shimizu, Shohko Miyamatsu, Kango Nohara, Tsutomu Sakurai, Takaaki Mizuno, Yuuki Yamashita

    A 69-year-old man visited a clinic for left leg weakness. With suspicions of lung cancer and a metastatic brain tumor, he was referred to our hospital and was diagnosed with large cell neuroendocrine carcinoma, cT1bN0M1b (BRA), stage IV. After stereotactic radiosurgery for his brain metastasis, he was treated with chemotherapy containing cisplatin and irinotecan. A week after initiating chemotherapy, he suddenly developed severe right leg pain and adynamia. A computed tomography angiogram revealed occlusion of the right common femoral artery, and percutaneous thrombectomy was performed. The symptoms resolved completely, and he was discharged without any sequelae or recurrence. Acute arterial occlusion of the limbs during chemotherapy is uncommon and requires prompt diagnosis and treatment; hence, caution should be paid when it is clinically suspected.

    • 1 April 2016
      • Vol. 36  (4) , 1767-71

    Phase II Study of Carboplatin and Pemetrexed in Advanced EGFR-wild-type Non-squamous Non-small Cell Lung Cancer: The Central Japan Lung Study Group Trial 0906.

    by Tomoki Kimura, Hiroyuki Taniguchi, Naohiro Watanabe, Hideo Saka, Yoshihito Kogure, Joe Shindo, Tomohiko Ogasawara, Eiji Kojima, Yoshinori Hasegawa, Masashi Yamamoto, et al.

    Several pre-clinical and clinical studies suggest a potential predictive role of epidermal growth factor receptor (EGFR) mutation in responsiveness to cytotoxic chemotherapy. The aim of this phase II study was to evaluate the efficacy and safety of pemetrexed-carboplatin combination as first-line chemotherapy in advanced non-squamous non-small cell lung cancer (NSCLC) limited to EGFR-wild-type cases. In this single-arm, multicenter clinical trial, patients received pemetrexed (500 mg/m(2)) and carboplatin (area under the curve=6) intravenously on day 1 every 3 weeks for three to six cycles. The objective response rate (ORR) was the primary end-point; secondary end-points included the disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and safety. A total of 54 patients were enrolled and 53 patients received therapy. No complete response was observed and partial response was observed in 19 (35.8%) cases, resulting in an ORR of 35.8% [95% confidence interval (CI)=23.1-50.2%]. Stable disease was observed in 20 (37.7%) patients and therefore the DCR was 73.6% (95% CI=59.7-84.7%). The median PFS was 5.4 months (95% CI=4.1-6.8 months) and the median OS was 12.7 months (95% CI=9.3-16.1 months). Treatment-related grade 3 or 4 hematological toxicities were neutropenia, leukopenia, anemia and thrombocytopenia in 35.8%, 11.3%, 30.2%, and 32.1% of patients, respectively. No grade 3 febrile neutropenia was observed, and grade 3 or 4 non-hematological toxicities were mild. There was no treatment-related death. The pemetrexed-carboplatin combination was effective and well-tolerated in patients with EGFR-wild-type non-squamous NSCLC (UMIN-CTR number: UMIN000003393).


  • Analysis of the relationship between health status and mortality in hypercapnic patients with noninvasive ventilation

    by Toru Oga, Hiroyuki Taniguchi, Hideo Kita, Tomomasa Tsuboi, Keisuke Tomii, Morihide Ando, Eiji Kojima, Hiromi Tomioka, Yoshio Taguchi, Yusuke Kaji, et al.

    Health status and mortality are important outcomes in patients with advanced pulmonary diseases receiving noninvasive ventilation (NIV). However, their relationship has not been thoroughly investigated. The present study prospectively recruited 56 stable outpatients treated with NIV for chronic hypercapnic respiratory failure caused by chronic obstructive pulmonary disease and/or pulmonary tuberculosis sequelae. At baseline, health status was measured by the Medical Outcomes Study 36-item short form, a generic questionnaire; the St. George's Respiratory Questionnaire (SGRQ), a respiratory-specific questionnaire; and two respiratory failure-specific questionnaires, the Maugeri Respiratory Failure questionnaire and the Severe Respiratory Insufficiency (SRI) questionnaire. Arterial blood gas, pulmonary function, dyspnea and psychological status were also measured. In cross-sectional comparisons of the four health status questionnaires, the SGRQ and SRI questionnaire had lower floor and ceiling effects. During the 3-year follow-up, 16 patients (29%) died. Health status shown by the SGRQ and SRI was significantly predictive of mortality, independently of the physiological measures of low body mass index (BMI), hypercapnia, and low pulmonary function. Stepwise multivariate analyses indicated that the SRI summary score was the most significant predictor of mortality (P = 0.0006) followed by BMI (P = 0.012). There was a significant relationship between health status and 3-year mortality in patients with NIV, independently of under-nutrition, hypercapnia and low pulmonary function. Health status measurement is important not only to comprehensively evaluate disease severity in relation to its close association with mortality, but also to elucidate factors that improve the survival of patients with advanced respiratory diseases.


  • Predictors and impact of time to clinical stability in community-acquired pneumococcal pneumonia

    by Kazuto Takada, Shuuichi Matsumoto, Eiji Kojima, Susumu Iwata, Kiyoko Ninomiya, Kentarou Tanaka, Daiki Goto, Takahiro Shimizu, Kango Nohara


    • 1 April 2011
      • Vol. 38  (4) , 697-700

    [A case of six metachronous primary malignancies].

    by Kazuto Takada, Shuichi Matsumoto, Eiji Kojima, Susumu Iwata, Shoutaro Okachi, Kiyoko Ninomiya, Hiroshi Morioka, Yasunori Enomoto, Kentaro Tanaka, Daiki Goto, et al.

    Recently, the early detection and the advances in therapy for malignant diseases have contributed to prolonged survival of patients, resulting in an increment of multiple primary malignancies. We describe a 55-year-old man, at the first presentation, with six malignancies over 14 years(malignant lymphoma, gastric cancer, ureteral cancer, small cell lung cancer, bladder cancer, and squamous cell lung cancer). A case of six primary malignancies is extremely rare and, as far as we know, this is the 16th case of its kind reported in Japan. The overlapping of many malignant diseases resulted in some difficulties with treatment. Whereas the ureteral cancer and small cell lung cancer were synchronous, considering the therapeutic duration of lung cancer, we proceeded with the operation for ureteral cancer and had to delay the start of chemotherapy for small cell lung cancer for more than one month. Moreover, dose intensity of the chemotherapy for the small cell lung cancer was limited by expectancy of augmented myelosuppression, due to the effect of prior chemotherapy for malignant lymphoma. However, a strong neutropenia-induced postoperative abdominal infection necessitated discontinuation of chemotherapy and treatment with radiotherapy alone. In addition, the therapies for the newly developed squamous cell lung cancer, the sixth malignancy, were also limited because of reduced lung function and myelopoiesis. In treatment or follow-up of patients with multiple primary malignancies, as opposed to those with a single malignant disease, the characteristics of other malignancies and the morbidities by preceding therapies must be considered.

    • 1 January 2011
      • Vol. 49  (1) , 57-61

    [A case of fulminant community-acquired Acinetobacter pneumonia in a healthy woman].

    by Hiroshi Morioka, Shuuichi Matsumoto, Eiji Kojima, Kazuto Takada, Masato Shizu, Shoutarou Okachi

    We describe a case of fulminant community-acquired Acinetobacter baumannii pneumonia. A 68-year-old woman, who had no past medical history, was admitted with septic shock and pneumonia of left lower lobe. Despite intensive treatment she died on day 3 after admission. To the best of our knowledge, this is the 4th report of community-acquired Acinetobacter pneumonia in Japan and the 1st report in a healthy patient. We report a case of Acinetobacter pneumonia and discuss the clinical characteristics of the community-acquired type compared with the hospital-acquired type.


    • 1 September 2010
      • Vol. 48  (9) , 644-8

    [Relationship between chronic obstructive pulmonary disease and gastroesophageal reflux disease defined by the Frequency Scale for the Symptoms of gastroesophageal reflux disease].

    by Kazuto Takada, Shuuichi Matsumoto, Tetsuo Hiramatsu, Eiji Kojima, Susumu Iwata, Masato Shizu, Shoutarou Okachi, Kiyoko Ninomiya, Hiroshi Morioka

    Little is known about gastroesophageal reflux disease (GERD) in chronic obstructive pulmonary disease (COPD) patients. The aim of this study was to investigate the prevalence, clinical characteristics and risk factors for GERD in COPD patients, based on the Frequency Scale for the Symptoms of GERD (FSSG). In 228 COPD patients, the prevalence of GERD was 26.7%, independent of COPD stage. Logistic regression multivariate analysis revealed significant risk factors for accompanying GERD were age (p = 0.009; odds ratio (OR), 0.933; 95% confidence interval (CI) 0.885 to 0.983) and number of COPD exacerbation within one year (p = 0.043; OR, 1.675; 95% CI, 1.075 to 2.764). The risk factors of COPD exacerbation were total FSSG score (p = 0.031; OR, 1.079; 95% CI, 1.007 to 1.156) and inhaled corticosteroid use (p = 0.003; OR, 3.238; 95% CI, 1.482 to 7.076). Moreover, the Spearman rank correlation test showed that FSSG score was weakly but significantly correlated with the number of COPD exacerbations (rs = 0.317, p < 0.001). In conclusion, the incidence of GERD in COPD patients is high, and the incidence of GERD is closely related to COPD exacerbation.


    • 1 August 2008
      • Vol. 46  (8) , 614-9

    [Predictors of survival in patients with chronic hypercapnic respiratory failure receiving domiciliary NPPV].

    by Kazuto Takada, Shuuichi Matsumoto, Tetsuo Hiramatsu, Eiji Kojima, Hiroaki Watanabe, Masato Sizu, Shoutarou Okachi, Kiyoko Ninomiya

    Fifty-four cases (36 men) with chronic hypercapnic respiratory failure were prescribed domiciliary NPPV during 9 years. COPD (26 patients) and sequelae of tuberclosis (16 patients) were the major primary diseases. At the initiation of NPPV, the age was 71.2 +/- 7.3 years-old (mean +/- standard deviation) and PaCO2 was 76.7 +/- 16.2Torr. Overall, the 1-year and 5-year survival rates were 63.8% and 26.0%, respectively. Multivariate analysis identified BMI (body mass index) (hazzard ratio : 0.837, p = 0.020) and the number of days of hospitalization during 1 year before NPPV (hazzard ratio: 1.013, p = 0.016) as predictors of survival. Patients with frequent hospitalization for exacerbation or with malnutrition had poor prognosis, so comprehensive supports aimed to improve general status are needed for patients with chronic respiratory failure received domiciliary NPPV.